Recommendations for the treatment of established fungal infections
- PMID: 18588522
- DOI: 10.1111/j.1445-5994.2008.01725.x
Recommendations for the treatment of established fungal infections
Abstract
Evidence-based guidelines for the treatment of established fungal infections in the adult haematology/oncology setting were developed by a national consensus working group representing clinicians, pharmacists and microbiologists. These updated guidelines replace the previous guidelines published in the Internal Medicine Journal by Slavin et al. in 2004. The guidelines are pathogen-specific and cover the treatment of the most common fungal infections including candidiasis, aspergillosis, cryptococcosis, zygomycosis, fusariosis, scedosporiosis, and dermatophytosis. Recommendations are provided for management of refractory disease or salvage therapies, and special sites of infections such as the cerebral nervous system and the eye. Because of the widespread use newer broad-spectrum triazoles in prophylaxis and empiric therapy, these guidelines should be implemented in concert with the updated prophylaxis and empiric therapy guidelines published by this group.
Similar articles
-
Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2008.Intern Med J. 2008 Jun;38(6b):457-67. doi: 10.1111/j.1445-5994.2008.01649.x. Intern Med J. 2008. PMID: 18588519
-
Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.Arch Intern Med. 1990 Nov;150(11):2258-64. Arch Intern Med. 1990. PMID: 2241435 Review.
-
Antifungal therapy in invasive fungal infections.Curr Opin Pharmacol. 2010 Oct;10(5):522-30. doi: 10.1016/j.coph.2010.06.002. Epub 2010 Jul 2. Curr Opin Pharmacol. 2010. PMID: 20598943 Review.
-
Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.Br J Haematol. 2009 Mar;144(5):629-41. doi: 10.1111/j.1365-2141.2008.07412.x. Epub 2008 Dec 11. Br J Haematol. 2009. PMID: 19120371 Review.
-
Systemic fungal infections: major problems in cancer patients.Indian J Cancer. 1994 Sep;31(3):180-4. Indian J Cancer. 1994. PMID: 8557296 Review.
Cited by
-
Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT).Indian Dermatol Online J. 2020 Jul 13;11(4):502-519. doi: 10.4103/idoj.IDOJ_233_20. eCollection 2020 Jul-Aug. Indian Dermatol Online J. 2020. PMID: 32832435 Free PMC article.
-
Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.BMC Infect Dis. 2017 Jul 10;17(1):481. doi: 10.1186/s12879-017-2573-8. BMC Infect Dis. 2017. PMID: 28693479 Free PMC article.
-
Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation.J Clin Lab Anal. 2017 Jan;31(1):e22011. doi: 10.1002/jcla.22011. Epub 2016 Jun 24. J Clin Lab Anal. 2017. PMID: 27337994 Free PMC article.
-
Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.Eur J Clin Microbiol Infect Dis. 2013 May;32(5):679-89. doi: 10.1007/s10096-012-1794-4. Epub 2012 Dec 28. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23271674 Clinical Trial.
-
An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole.Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1173-9. doi: 10.1007/s10096-011-1425-5. Epub 2011 Oct 5. Eur J Clin Microbiol Infect Dis. 2012. PMID: 21971820 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
